Campbell & CO Investment Adviser LLC Acquires 862 Shares of Verona Pharma plc (NASDAQ:VRNA)

Campbell & CO Investment Adviser LLC increased its stake in Verona Pharma plc (NASDAQ:VRNAFree Report) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,836 shares of the company’s stock after purchasing an additional 862 shares during the period. Campbell & CO Investment Adviser LLC owned 0.06% of Verona Pharma worth $1,011,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Verona Pharma by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,467,571 shares of the company’s stock valued at $72,821,000 after acquiring an additional 164,268 shares during the period. Federated Hermes Inc. lifted its position in Verona Pharma by 49.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,493,530 shares of the company’s stock valued at $40,645,000 after purchasing an additional 822,832 shares during the period. Jennison Associates LLC boosted its stake in shares of Verona Pharma by 9.9% in the 4th quarter. Jennison Associates LLC now owns 1,585,385 shares of the company’s stock valued at $31,517,000 after purchasing an additional 142,819 shares during the last quarter. First Turn Management LLC bought a new stake in shares of Verona Pharma during the fourth quarter worth $23,981,000. Finally, Eventide Asset Management LLC bought a new stake in Verona Pharma in the 3rd quarter valued at $13,855,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma Stock Performance

Shares of Verona Pharma stock opened at $12.14 on Thursday. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $23.07. The company has a current ratio of 18.40, a quick ratio of 18.40 and a debt-to-equity ratio of 0.22. The business’s 50 day moving average is $14.62 and its 200-day moving average is $16.04.

Verona Pharma (NASDAQ:VRNAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.08). On average, equities research analysts predict that Verona Pharma plc will post -1.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on VRNA shares. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Verona Pharma in a research report on Friday, March 1st. HC Wainwright lowered their price objective on shares of Verona Pharma from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Finally, Piper Sandler increased their target price on shares of Verona Pharma from $31.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, April 16th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma presently has a consensus rating of “Buy” and a consensus target price of $33.20.

View Our Latest Report on VRNA

Insiders Place Their Bets

In other Verona Pharma news, insider Kathleen A. Rickard sold 36,248 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total value of $71,046.08. Following the sale, the insider now owns 2,621,552 shares in the company, valued at $5,138,241.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.80% of the company’s stock.

Verona Pharma Company Profile

(Free Report)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Read More

Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma plc (NASDAQ:VRNAFree Report).

Institutional Ownership by Quarter for Verona Pharma (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.